PT  - JOURNAL ARTICLE
AU  - Janice M. Leung
AU  - Chen X. Yang
AU  - Anthony Tam
AU  - Tawimas Shaipanich
AU  - Tillie-Louise Hackett
AU  - Gurpreet K. Singhera
AU  - Delbert R. Dorscheid
AU  - Don D. Sin
TI  - ACE-2 Expression in the Small Airway Epithelia of Smokers and COPD Patients: Implications for COVID-19
AID  - 10.1101/2020.03.18.20038455
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.03.18.20038455
4099  - http://medrxiv.org/content/early/2020/03/23/2020.03.18.20038455.short
4100  - http://medrxiv.org/content/early/2020/03/23/2020.03.18.20038455.full
AB  - Introduction Coronavirus disease 2019 (COVID-19) is a respiratory infection caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). This virus uses the angiotensin converting enzyme II (ACE-2) as the cellular entry receptor to infect the lower respiratory tract. Because individuals with chronic obstructive pulmonary disease (COPD) are at increased risk of severe COVID-19, we determined whether ACE-2 expression in the lower airways was related to COPD and cigarette smoking.Methods Using RNA-seq, we determined gene expression levels in bronchial epithelia obtained from cytologic brushings of 6th to 8th generation airways in individuals with and without COPD. We eternally validated these results from two additional independent cohorts, which used microarray technologies to measure gene expression levels from 6th to 12th generation airways.Results In the discovery cohort (n=42 participants), we found that ACE-2 expression levels were increased by 48% in the airways of COPD compared with non-COPD subjects (COPD=2.52±0.66 log2 counts per million reads (CPM) versus non-COPD= 1.70±0.51 CPM, p=7.62×10−4). There was a significant inverse relationship between ACE-2 gene expression and FEV1% of predicted (r=-0.24; p=0.035). Current smoking also significantly increased ACE-2 expression levels compared with never smokers (never current smokers=2.77±0.91 CPM versus smokers=1.78±0.39 CPM, p=0.024). These findings were replicated in the two eternal cohorts.Conclusions ACE-2 expression in lower airways is increased in patients with COPD and with current smoking. These data suggest that these two subgroups are at increased risk of serious COVID-19 infection and highlight the importance of smoking cessation in reducing the risk.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNAFunding StatementCIHRAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available on GEO or upon request from senior author (DDS)